Carboplatin

Carboplatin · CARBOPLATIN 10 mg/mL · Injection · Intravenous · Accord Healthcare, Inc.

NDC 16729-0295-33 · 1 VIAL, MULTI-DOSE in 1 CARTON / 15 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “requirements related to complying with good manufacturing practices”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$19.00

Reported to Texas DSHS · 2024 annual filing · Accord Healthcare, Inc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2023)

$802

36 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Intas Pharmaceuticals LimitedIndia
analysis · manufacture

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $53.36 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: ANDA206775
TE code: AP
Approval date: Feb 9, 2017
Patents / exclusivity: None on file

Shortage history

In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)Apr 28, 2023
Requirements related to complying with good manufacturing practices
month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)Apr 28, 2023
Discontinuation of the manufacture of the drug
month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)Apr 28, 2023
Discontinuation of the manufacture of the drug
month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)Apr 28, 2023
Requirements related to complying with good manufacturing practices
month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)Apr 28, 2023
month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
In shortage now — Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)Apr 28, 2023
month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Carboplatin (Injection)

Labeler	Strength	First seen	Last seen
Accord Healthcare, Inc.	CARBOPLATIN 10 mg/mL	Jul 15, 2026	Sep 2, 2026
Avyxa Pharma, LLC	CARBOPLATIN 500 mg/50mL	Jul 15, 2026	Sep 2, 2026
Avyxa Pharma, LLC	CARBOPLATIN 80 mg/8mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Carboplatin — NDC 16729-0295-33," retrieved September 3, 2026, https://drugdashboards.com/drug/16729029533.

Free to cite with attribution — see how the data is put together.